circCSNK1G1 can upregulate ZNF217 and then accelerate the progression of GC by promoting the expression of miR-758, implying that circCSNK1G1 could be employed as a diagnostic or therapeutic biomarker for GC [192]. This evidence concerns the gene ZNF217 and gastric cancer.